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Background: Recently, some studies have focused on the tumor angiogenesis
and its prognostic value. We studied the expression of vascular endothelial
growth factor, microvessel counts, and serum concentrations of vascular
endothelial growth factor to investigate their association with clinicopathologic
factors and prognosis in non-small-cell lung cancer. Methods: The expression
of vascular endothelial growth factor was determined by an immunohisto-
chemical analysis from 91 paraffin specimens of completely resected non-
small-cell lung cancers using anti–growth factor polyclonal antibody. Mi-
crovessel staining was performed by immunohistochemical analysis with
anti–factor VIII–related antigen polyclonal antibody. Measurement of the
serum concentrations of vascular endothelial growth factor used the sandwich
enzyme-linked immunosorbent assay technique. Results: Expression of vascu-
lar endothelial growth factor was detected in 48 of the 91 tumors. The positive
ratio was significantly higher in patients with adenocarcinoma than in those
with squamous cell carcinoma. The microvessel counts were significantly
higher in the patients with nodal metastasis than in those without nodal
metastasis. The serum concentrations of vascular endothelial growth factor
were also significantly higher in the patients with T3-4 disease than in those
with T1-2 disease. The microvessel counts were closely associated with expres-
sion of vascular endothelial growth factor. The prognosis of patients with a
positive growth factor ratio was significantly worse than that of the patients
with a negative ratio (p 5 0.002), especially in squamous cell carcinoma.
According to a multivariate analysis, only nodal status and expression of
vascular endothelial growth factor were found to be independent prognostic
factors. Conclusions: The expression of vascular endothelial growth factor was
one of the most important prognostic factors in completely resected non-small-
cell lung cancer, especially in squamous cell carcinoma. (J Thorac Cardiovasc
Surg 1998;115:1007-14)
Angiogenesis is required for the growth and me-tastasis of solid tumors.l,2 Tumor angiogenesis is
also closely associated with prognosis3-6 and may be
regulated by angiogenic factors, which are produced
by the tumor cells.7-10 Recently, several angiogenic
factors, such as fibroblast growth factor,8 hepatocyte
growth factor,9 and platelet-derived growth factor,10
have been identified. Vascular endothelial growth
factor (VEGF), also known as vascular permeability
factor, is one such factor that is a homodimeric 34 to
42 kDa, heparin-binding glycoprotein with potent
angiogenic, mitogenic, and vascular permeability–
enhancing activities specific for endothelial cells.11-13
The gene for human VEGF is organized into eight
exons. As a result of alternative splicing, four tran-
scripts encoding mature monomeric VEGF contain-
ing 121, 165, 189, and 206 amino acid residues
(VEGF121, VEGF165, VEGF189, and VEGF206)
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have also been detected. VEGF121 and VEGF165 are
diffusible proteins that are secreted into the me-
dium. On the other hand, VEGF189 and VEGF206
have a high affinity for heparin and are mostly
bound to heparin-containing proteoglycans in the
extracellular matrix.11-13 VEGF has been identified
in some malignant tumors, for example, ovarian
cancer,14 melanoma,15 and gastric cancer.16 It has
also been identified in lung cancer17; however, there
has been no report on VEGF expression as a
prognostic factor.
Recently, the postoperative prognosis has im-
proved in non-small-cell lung cancer (NSCLC),18
but this prognosis still remains worse than for other
carcinomas. In this study, we examined the VEGF
expression in tumor tissue to investigate the corre-
lation with clinicopathologic factors and prognosis
in patients with completely resected NSCLC. In
addition, we also examined the microvessel counts
that closely reflect angiogenesis in tumor tissue.
Thanks to recent advances in medical technology, a
serum assay of VEGF concentrations can now be
easily performed. We also examined the serum
VEGF concentrations to investigate both their clin-
ical value and correlation with VEGF expression.
Materials and methods
Samples. Resected specimens from 91 consecutive pa-
tients with lung adenocarcinoma or squamous cell carci-
noma who could be followed completely and who under-
went a complete surgical resection at our institution from
September 1991 to March 1995 were studied. The median
follow-up period was 725 days. The patients ranged in age
from 38 to 80 years (average, 65.6 6 9.7 years); 69 were
men and 22 were women. All patients underwent diagnos-
tic procedures before the operation, including brain com-
puted tomography, body computed tomography, and bone
scintiscan without mediastinoscopy. The histologic types
included 57 adenocarcinomas and 34 squamous cell car-
cinomas. The pathologic stage was classified according to
the International Staging System for Lung Cancer19 after
a complete mediastinal lymph node dissection was carried
Fig. 1. Immunohistochemical staining of VEGF. A, Positive VEGF immunostaining of squamous cell
carcinoma. VEGF was mainly localized in the cytoplasm of the tumor cells (original magnification 3400).
B, Negative VEGF immunostaining of squamous cell carcinoma (original magnification 3400).
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out in all cases: stage I in 32 patients, stage II in 7 patients,
stage IIIA in 32 patients, and stage IIIB in 20 patients. Of
the 20 patients with stage IIIB disease, 18 had T4 N0-2
disease and 2 had T1-3 N3 disease. A complete resection
was defined as no gross and microscopic residual tumor
remaining at the bronchial or vascular stump. Even if
microscopic metastasis were present in the highest medi-
astinal lymph node, it was still considered a complete
resection. The slides were reviewed independently by two
observers (H.I. and T.O.) who had no knowledge of the
patients’ clinical data.
Immunohistochemical staining of VEGF. Formalin-
fixed, paraffin-embedded tissue specimens were prepared
by conventional techniques. Immunohistochemical studies
were performed with the labeled streptoavidin-biotin
method with anti–VEGF rabbit polyclonal antibody A-20
(Santa Cruz Biotechnology, Santa Cruz, Calif.). This
antibody recognizes the 121, 165, and 189 isoforms of
VEGF. Five-micrometer–thick sections were dewaxed in
xylene, taken through ethanol, and then incubated with
0.3% hydrogen peroxide in methanol for 30 minutes to
block any endogenous peroxidase activity. Then the sec-
tions were reacted with VEGF antibody (negative controls
with nonspecific rabbit serum) in a 1:200 dilution at room
temperature for 2 hours. The Labeled Streptavidim Biotin
kit (Dako Corp., Carpintera, Calif.) provided the second-
ary reagents. After these treatments were completed, the
diaminobenzidine method was next used to visualize
peroxidase with hematoxylin as a counterstain.
The degree of polyclonal antibody reactivity with indi-
vidual tissue sections was considered to be positive if
unequivocal staining of the membrane or cytoplasm was
seen in more than 5% of the tumor cells in the slide of the
largest section of the tumor, as reported by Maeda and
associates.16
Microvessel staining and counting. Microvessels in the
tumor tissue were highlighted by immunohistochemical
staining with anti-factor VIII–related antigen polyclonal
antibody A0082 (Dako) in a 1:200 dilution at room
temperature for 2 hours. The other method was the same
as VEGF immunohistochemical staining. As described in
another report,5 any single brown-stained cells or clusters
of endothelial cells that were clearly separate from the
adjacent microvessels, tumor cells, and other connective
tissue elements were considered as a vessel. The vessels
were counted in the five areas of highest vascular density
at 2003 magnification, as described in another report.5
The microvessel counts were expressed as the mean
number of vessels in these areas.
Enzyme-linked immunosorbent assay (ELISA) of se-
rum VEGF. After informed consent had been obtained
from all patients, the serum from 57 of the 91 patients was
stocked before the operation and frozen at –80° C. The
sera were then melted at room temperature within 15
minutes before being subjected to an assay. The serum
VEGF assay used the quantitative sandwich ELISA tech-
nique with the VEGF ELISA kit (R&D Systems, Inc.,
Minneapolis, Minn.) according to the manufacturer’s in-
structions. Two antibodies in this assay reacted mainly to
Table I. Correlation between the VEGF expression
in tumor tissue and the clinicopathologic factors in
91 patients
Factors
No. of patients (%)
Total
VEGF-
positive
VEGF-
negative
p
Value
Total patients 91 48 (52.7) 43
Age (yr)
,65 40 23 (57.5) 17 0.42
65% 51 25 (49.0) 26
Sex
Male 69 38 (55.1) 31 0.43
Female 22 10 (45.5) 12
Histologic type
Adenocarcinoma 57 35 (61.4) 22 0.03
Squamous cell
carcinoma
34 13 (38.2) 21
T stage
T1-2 54 27 (50.0) 27 0.52
T3-4 37 21 (56.8) 16
Nodal status
Positive 48 25 (52.1) 23 0.89*
N1 18 6 (33.3) 12
N2 28 17 (60.1) 11
N3 2 2 (100) 0
Negative 43 23 (53.5) 20
Pathologic stage
I 32 19 (59.4) 13 0.50†
II 7 0 (0.0) 7
IIIA 32 16 (50.0) 16
IIIB 20 13 (65.0) 7
VEGF, Vascular endothelial growth factor.
The p value was calculated between NO and N1-3* and between stage I-II
and stage III.†
Table II. Correlation between the microvessel
counts, serum VEGF concentrations, and various
prognostic factors
Factors
Microvessel counts
Serum VEGF
concentrations
Counts/2003*
p
Value Pg/ml*
p
Value
Total 85.9 6 71.8 525 6 442
Histologic type
Adenocarcinoma 96.8 6 84.1 0.058 589 6 493 0.13
Squamous cell
carcinoma
67.4 6 38.7 398 6 289
T stage
T1-2 76.9 6 62.5 0.15 393 6 255 0.004
T3-4 98.9 6 82.6 733 6 583
Nodal status
Positive 100.1 6 84.3 0.04 596 6 499 0.20
Negative 70.6 6 52.0 443 6 358
Pathologic stage
I-II 67.3 6 52.8 0.03 365 6 224 0.02
III 99.8 6 80.9 644 6 524
VEGF, Vascular endothelial growth factor.
*Mean 6 standard deviation.
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VEGF165. The optical density was determined within 30
minutes after these treatments were performed with a
microtiter plate reader set to 450 nm. After averaging the
duplication of this treatment for each sample, the concen-
trations of serum VEGF were calculated with a standard
curve. The standard curve of VEGF was linear in a plot at
concentrations from 0 to 2000 pg/ml (r 5 0.998, p 5 0.0001).
Statistical analysis. The microvessel counts and serum
VEGF concentrations were expressed as the mean 6
standard deviation. The relationship between the VEGF
expression and various clinicopathologic factors were ex-
amined with the x2 test. The relationship between the
microvessel counts, serum VEGF concentrations, and
clinicopathologic factors were examined with the unpaired
Student’s t test. The relationship between the microvessel
counts and serum VEGF concentrations was examined
with the Spearman rank test. The survival curves were
calculated with the Kaplan-Meier method and were then
analyzed by the log rank test. A univariate and a multi-
variate analysis of various prognostic factors were assessed
by the Cox’s proportional-hazards regression model.20
Results
The immunohistochemical detection of VEGF ex-
pression. VEGF was mainly localized in the cyto-
plasm of the tumor cells (Fig. 1). Tumor cells that
stained strongly for VEGF were observed more
often in the invasive front than in the center of the
tumor, especially in squamous cell carcinoma. On
the other hand, VEGF stained relatively homoge-
neously in adenocarcinoma.
VEGF expression was detected in 48 of the 91
tumors (52.7%). Table I shows the correlation be-
tween the VEGF expression and various clinico-
pathologic factors. A significant difference was
noted with histologic types. The VEGF-positive rate
was significantly higher in patients with adenocarci-
noma than in those with squamous cell carcinoma (p 5
0.03). However, there was no significant association
between the VEGF expression and the age at opera-
tion, sex, T stage, nodal status, or pathologic stage.
Microvessel counts and serum VEGF concentra-
tions. Table II shows the correlation between mi-
crovessel counts, serum VEGF concentrations, and
various clinicopathologic factors. Microvessel
counts ranged from 7 to 321 counts/2003 with a
mean of 85.9 6 71.8 counts/2003, and serum VEGF
concentrations ranged from 0 to 2014 pg/ml with a
mean of 525 6 442 pg/ml. Microvessel counts and
serum VEGF concentrations were not significantly
associated with the histologic types. The microvessel
counts and serum VEGF concentrations in patients
with stage III disease were significantly higher than
in those patients with stage I-II disease (p 5 0.03
and p 5 0.02, respectively). The microvessel counts
in the tumors with nodal metastasis were also sig-
nificantly higher than in those without nodal metas-
tasis (p 5 0.04). However, the T stage was not
significantly associated with the microvessel counts.
On the other hand, the serum VEGF concentrations
were significantly associated with the T stage. The
serum VEGF concentrations were significantly
higher in patients with T3-4 disease than in those
with T1-2 disease (p 5 0.004) However, the nodal
status was not significantly associated with the se-
rum VEGF concentrations.
Relationship between VEGF expression and mi-
crovessel counts or serum VEGF concentrations.
There was a significant association between the
VEGF expression and the microvessel counts in the
tumor tissue. The microvessel counts were signifi-
Fig. 2. Survival curves of the 91 patients according to the
VEGF expression.
Fig. 3. Survival curves of the 34 patients with squamous
cell carcinoma according to the VEGF expression.
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cantly higher in patients with VEGF-positive tumor
(102.9 6 83.3) than in patients with VEGF-negative
tumor (66.8 6 50.6) (p 5 0.01). On the other hand,
there was no significant association between the
VEGF expression and the serum VEGF concentra-
tions (Table III). There was no significant associa-
tion between the serum VEGF concentrations and
the microvessel counts (p 5 0.78).
Survival analysis. The prognosis of the 48 pa-
tients with VEGF-positive tumor was significantly
worse than the 43 patients with VEGF-negative
tumor (p 5 0.003) (Fig. 2). Table IV shows a
univariate analysis of the various prognostic factors.
T stage, nodal status, and VEGF expression were all
statistically significant factors (p 5 0.004, p 5
0.0001, and p 5 0.003, respectively). The microves-
sel counts might appear to be a prognostic factor but
not reach statistical significant (p 5 0.083); however,
the serum VEGF concentrations were not an impor-
tant prognostic factor (p 5 0.34). A multivariate
analysis with Cox’s proportional-hazards regression
model was performed to investigate the indepen-
dent prognostic factors among the T stage, nodal
status, VEGF expression, and microvessel counts.
As a result, only the nodal status (p 5 0.0001) and
VEGF expression (p 5 0.004) were identified to be
independent prognostic factors (Table V). Because
the incidence of VEGF expression differed signifi-
cantly between the patients with squamous cell
carcinoma and adenocarcinoma, univariate and
multivariate subset survival analysis were performed
on each histologic type. Especially in the 34 patients
with squamous cell carcinoma, the prognosis of the
patients with VEGF-positive tumor was significantly
worse than for patients with VEGF-negative tumor
(p 5 0.0001) (Fig. 3). The same tendency was also
observed in patients with adenocarcinoma, but it did
not reach statistical significance (p 5 0.19). Accord-
ing to multivariate analysis on each histologic type,
VEGF expression was also an independent prognos-
tic factor in patients with squamous cell carcinoma
(p 5 0.03); however, it did not reach statistical
significant in patients with adenocarcinoma (p 5
0.24).
Discussion
In this study, we detected the VEGF-positive
expression in 48 of 91 patients (52.7%) with a
completely resected stage I-III NSCLC. We ob-
served no significant correlation between the VEGF
expression and age, sex, T stage, nodal status, or
pathologic stage. A significant relationship was only
seen in the VEGF expression regarding histologic
types. The positive ratio of VEGF expression in
adenocarcinoma was higher than that in squamous
cell carcinoma (p 5 0.03). We also found a tendency
that microvessel counts were higher in patients with
adenocarcinoma than in those with squamous cell
carcinoma. These findings mean that adenocarci-
noma has higher angiogenic potential than squa-
mous cell carcinoma. Recently, some reports21, 22 on
genetic studies have shown a difference in the
incidence of certain genetic changes in histologic
type of lung cancer. For example, ras mutations are
found predominantly in adenocarcinoma,21 whereas
p53 gene mutations are more prevalent in squamous
cell carcinoma than in adenocarcinoma.22 Such dif-
ferences in the histologic type in lung cancer may be
identified in both angiogenic factors and genetic
changes.
Weidner and associates23 reported that the mi-
crovessel counts were closely associated with lymph
nodal metastasis in invasive breast cancer; other
authors have reported them to be correlated with
systemic metastasis in NSCLC.24, 25 In this study, the
microvessel counts were closely associated with
lymph nodal metastasis; moreover, the microvessel
counts in VEGF-positive tumors were also signifi-
cantly higher than in VEGF-negative tumors. It is
therefore thought that VEGF might reflect the
metastatic potential through the angiogenesis of the
tumor.
Table III. Correlation between VEGF expression in tumor tissue, the microvessel counts, and serum
VEGF concentrations
Factors
Microvessel counts Serum VEGF concentrations
Counts/2003* p Value Pg/ml* p Value
VEGF expression
Positive 102.9 6 83.3 0.01 606 6 552 0.20
Negative 66.8 6 50.6 451 6 300
VEGF, Vascular endothelial growth factor.
*Mean 6 standard deviation.
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In this study, we also studied serum VEGF con-
centrations using ELISA. The serum VEGF was
found to be associated with T stage, but no associ-
ation was seen with nodal status. We also studied
serum VEGF concentrations of 61 healthy persons
(mean age: 63 years; male/female: 47/14). The se-
rum VEGF concentrations of healthy persons was
181 6 165 pg/ml. This was lower than that of
patients with NSCLC. Moreover, we studied serum
VEGF concentrations after surgery. We obtained
the sample at 1 to 3 months after surgery because
wound healing might increase the serum VEGF
level through angiogenic response immediately after
surgery. The serum VEGF was decreased after
surgical resection from 525 6 442 pg/ml to 243 6
214 pg/ml (detailed data not shown). It appeared
that the serum VEGF increased with growth of the
tumor and also might reflect the tumor burden. A
serum assay can be easily and frequently performed
because of its minimal invasiveness compared with
surgical examination of resected tissue material.
Dirix and associates26 reported that the serum
VEGF might prove a useful tool in the quantifica-
tion of angiogenesis and might be of valuable infor-
mation in the decision process of initiating palliative
chemotherapy in colorectal cancer. Moreover, we
think that an evaluation of serum VEGF is useful
for both a serologic diagnosis and the monitoring of
the tumor burden. We have not yet checked serum
VEGF in patients with recurrence, and we should
examine the values for a longer period. In this study,
there was no significant association between the
VEGF expression in tumor tissue and the serum
VEGF concentrations. This discrepancy may be due
to differences in the use of antibodies for each assay,
such as anti-VEGF121 for IHC and anti-VEGF165
for ELISA. In addition, the mechanism of VEGF
shedding from the tumor cell to the systemic circu-
lation has not yet been clearly elucidated and may
also be one of the reasons for this discrepancy.
The most interesting finding in this study was the
prognostic impact of VEGF expression in patients
with completely resected NSCLC. Toi and associ-
ates27, 28 reported the VEGF expression to be a
significant prognostic factor in patients with breast
cancer. However, there has been no report that
shows the VEGF expression to be associated with
prognosis for patients with NSCLC. We found that
the prognosis for patients with VEGF-positive tu-
mor was significantly worse than that for patients
Table IV. Univariate analysis of the various prognostic factors
Factors
Characteristics
Risk ratio 95% CI p ValueUnfavorable Favorable
Age 65# ,65 0.899 0.500-1.615 0.72
Sex Male Female 0.882 0.455-1.710 0.71
Histologic types Adenocarcinoma Squamous cell
carcinoma
0.885 0.487-1.609 0.69
T stage T3-4 T1-2 2.358 1.307-4.255 0.004
Nodal status Positive Negative 4.743 2.381-9.451 0.0001
VEGF expression Positive Negative 2.588 1.373-4.878 0.003
Microvessel counts High Low* 1.697 0.933-3.089 0.083
Serum VEGF concentrations High Low† 0.695 0.328-1.473 0.34
CI, Confidence interval; VEGF, vascular endothelial growth factor.
*The cut off value represents the mean of all microvessel counts (85.9 counts/2003).
†The cut off value represents the mean of serum VEGF concentrations (525 pg/ml).
Table V. Multivariate analysis of various prognostic factors
Factors
Characteristics
Risk ratio 95% CI p ValueUnfavorable Favorable
T stage T3-4 T1-2 0.663 0.352-1.249 0.20
Nodal status Positive Negative 4.245 2.029-8.878 0.0001
VEGF expression Positive Negative 2.590 1.349-4.973 0.004
Microvessel counts High Low* 1.282 0.694-2.369 0.42
CI, Confidence interval; VEGF, vascular endothelial growth factor.
*The cut off value represents the mean of all microvessel counts (85.9 counts/2003).
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with VEGF-negative NSCLC. Harpole and associ-
ates29 have reported that angiogenesis was the most
significant prognostic factor in stage I lung cancer.
In 32 patients with stage I in this study, the VEGF
expression was not significant prognostic factor (p 5
0.12). However, only one of 13 patients with VEGF-
negative tumor died. On the other hand, 6 of 19
patients with VEGF-positive tumor died. Thus
VEGF expression may be one of the most important
prognostic factors in early stage lung cancer. Ac-
cording to a multivariate analysis using Cox’s pro-
portional-hazards regression model, the VEGF ex-
pression was found to be an independent significant
prognostic factor along with nodal status. Because
the incidence of VEGF expression differed signifi-
cantly between the patients with squamous cell
carcinoma and adenocarcinoma, univariate and
multivariate survival analyses were performed on
each histologic type. As a result, especially in pa-
tients with squamous cell carcinoma, the expression
of VEGF was found to be closely associated with the
prognosis and to be an independent prognostic
factor.
In conclusion, the VEGF expression is one of the
most important prognostic factors; the evaluation of
the VEGF expression may be effective when adju-
vant therapy is considered for patients with com-
pletely resected NSCLC, including antiangiogenic
therapy.30
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